Welcome to our dedicated page for Silexion Therapeutics SEC filings (Ticker: SLXN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Silexion’s filings can feel like decoding lab notes. Clinical data tables, RNA interference protocols, and financing footnotes sprawl across hundreds of pages, yet every detail may move the stock before the next trial read-out. If you have ever typed “Silexion SEC filings explained simply” or wondered whether the latest 8-K covered new KRAS results, you are not alone.
Stock Titan solves that problem. Our AI instantly converts dense disclosures into clear takeaways—highlighting cash runway, trial milestones, and partnership clauses—so you can focus on decisions, not document searches. Need to monitor “Silexion insider trading Form 4 transactions” or get a “Silexion quarterly earnings report 10-Q filing” the moment it hits EDGAR? We deliver real-time alerts and plain-English summaries, all in one place.
Here is what you will find on this page:
- “Silexion annual report 10-K simplified” to spot R&D spend and dilution risk.
- “Silexion Form 4 insider transactions real-time” tracking executive sentiment and option exercises.
- “Silexion proxy statement executive compensation” showing how management is rewarded for RNAi milestones.
- “Silexion 8-K material events explained” including clinical data releases or new Evonik agreements.
- “Silexion earnings report filing analysis” with AI-flagged shifts in trial timelines.
From “understanding Silexion SEC documents with AI” to catching a sudden “Silexion executive stock transactions Form 4,” every filing type is covered—10-K, 10-Q, 8-K, S-1, DEF 14A, and more—updated the second EDGAR posts. Spend less time untangling scientific jargon and more time evaluating whether SIL-204’s next data drop aligns with your investment thesis.
Silexion Therapeutics Corp (SLXN) is a clinical-stage biotech developing SIL204, a second-generation siRNA targeting mutant KRAS in oncology. The company reported a net loss of $4.238 million for the six months ended June 30, 2025 and had $3.466 million of cash and cash equivalents on hand at that date. Operating cash outflow for the six months was $4.96 million and the accumulated deficit was $47.5 million. Management disclosed substantial doubt about the company’s ability to continue as a going concern for 12 months without additional financing.
The company completed equity financings in January 2025 (gross proceeds ~$5.0 million) and inducement warrant exercises raising ~$3.276 million through June 30, 2025, and used an equity line of credit (ELOC) raising an aggregate of $3.1 million through June 30, 2025. Nasdaq trading and listing matters required two reverse share splits (1-for-9 and 1-for-15) and the company received a hearings panel decision allowing continued listing subject to a compliance plan to reach $2.5 million of shareholders equity by September 19, 2025.
Silexion Therapeutics Corp filed a Form D reporting new warrants issued on 2025-08-01 and an aggregate offering amount of $3,597,662, which equals the exercise price of those new warrants. The filing states total amount sold $3,597,662 with $0 remaining. The new instruments include 304,212 investor warrants at $11.32/share and 10,647 agent warrants at $14.4625/share. The issuer is a Cayman Islands corporation formed in 2024 with its principal place of business in Ramat Gan, Israel.
The company reports No Revenues and 11 investors in this offering. It relied on Rule 506(b) and engaged H.C. Wainwright as the associated broker-dealer. Reported fees include $140,789 in sales commissions and $909,500 in finders' fees. Silexion expects any proceeds from future exercise of the new warrants to be used for general corporate purposes and states $0 will be paid to executive officers, directors, or promoters.
Silexion Therapeutics (SLXN) filed an 8-K announcing a 1-for-15 reverse share split effective after the 28-Jul-25 close. Authorized capital stays US$20,000 but is now divided into 1,481,482 ordinary shares; par value rises to US$0.0135. All issued and outstanding shares are reduced proportionally and will begin trading on a split-adjusted basis under the same ticker at the 29-Jul-25 open. The new ordinary-share CUSIP is G1281K 130.
The company simultaneously delivered a Warrant Adjustment Notice. Each pre-split warrant is now exercisable for 1/15th of a share, and the exercise price is lifted 15× to US$1,552.50 per post-split share. Fractional entitlements will be rounded up at the broker (DTC participant) level. Warrant CUSIP (G1281K 114) and ticker (SLXNW) are unchanged.
The split was approved at the 14-Jul-25 AGM and effected through an amendment to the Amended & Restated Memorandum of Association, filed 28-Jul-25. Items 3.03 and 5.03 detail the warrant modifications and charter amendment, while Item 8.01 incorporates these events by reference.
Silexion Therapeutics Corp (SLXN) will hold an extraordinary general meeting in Aug-2025 to vote on a single item: increasing authorised share capital to US$121,500 divided into 9,000,000 ordinary shares (par US$0.0135) from the post-reverse-split level of 1,481,482 shares.
The board says the extra 7.5 m shares are essential to (1) regain and thereafter maintain compliance with Nasdaq Listing Rule 5550(b)(1) – minimum US$2.5 m shareholders’ equity by 19-Sep-2025 – following a favourable Nasdaq hearings-panel decision on 7-Jul-2025, and (2) fund pre-clinical/clinical RNAi programs and potential business-development deals. Current capacity is only 529,302 unissued shares, viewed as inadequate for equity raises, warrant/option exercises, conversion of a US$3.433 m sponsor note and employee incentives.
The proposed authorisation represents a 507% increase in total authorised shares. The board unanimously recommends voting FOR. Failure would likely trigger Nasdaq delisting. Risks highlighted include substantial dilution, potential share-price pressure and anti-takeover uses of the new shares.
On July 16 2025 Silexion Therapeutics Corp ("SLXN") filed an 8-K announcing a 1-for-15 reverse share split affecting all issued, outstanding and authorized ordinary shares. The split will be effected automatically after market close on 28 Jul 2025, and the shares will begin trading on a split-adjusted basis on Nasdaq at the open on 29 Jul 2025; the ticker remains "SLXN".
- Every 15 existing shares convert into 1 new share.
- Par value increases from $0.0009 to $0.0135 per share.
- No fractional shares will be issued; DTC positions will be rounded up to the nearest whole share.
The Board’s goal is to raise the per-share price to maintain compliance with Nasdaq Capital Market listing standards. Warrants ("SLXNW") are expected to be adjusted pursuant to their terms. Additional details are provided in the press release attached as Exhibit 99.1.
FAQ
What is the current stock price of Silexion Therapeutics (SLXN)?
What is the market cap of Silexion Therapeutics (SLXN)?
